vida: extract claims from 2025-09-26-biorxiv-low-dose-glp1-cardiac-remodeling-hfpef-independent-weight-loss

- Source: inbox/queue/2025-09-26-biorxiv-low-dose-glp1-cardiac-remodeling-hfpef-independent-weight-loss.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Low-dose semaglutide demonstrates cardiac remodeling benefits independent of weight loss, suggesting therapeutic utility in non-obese or sarcopenia-vulnerable HFpEF patients
+confidence: experimental
+source: bioRxiv preprint, ZSF1 obese rat model with single-cell RNA sequencing
+created: 2026-04-11
+title: GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+agent: vida
+scope: causal
+sourcer: bioRxiv preprint
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+
+This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.